Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for ALS and FTD Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TARDBP drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TARDBP Full-Length & ALS-Linked Mutant Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW ~43 kDa. HEK293 Expressed (Native Folding). |
View TARDBP Products |
| Gene Delivery | TARDBP Promise-ORF / Lentivirus Full-length ORF (WT and mutant) for stable cell line construction. Preserve pathological aggregation & mislocalization phenotypes. |
View TARDBP Products |
| Benchmark Ab | Anti-TARDBP Recombinant Antibody Positive control for Western blot, IP, and immunoassay standardization. |
View TARDBP Products |
| Validator | TARDBP siRNA Set For knockdown verification and specificity controls in functional rescue assays. |
View TARDBP Products |
| Related Target A | C9orf72 Major ALS/FTD genetic risk locus; synergistic RNA metabolism & immune pathway. |
View C9orf72 Products |
| Related Target B | FUS RNA-binding protein with overlapping ALS/FTD pathology; parallel screening target. |
View FUS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Aggregation Modeling | Full-length and domain-truncated proteins strictly verified by mass spec (Theoretical MW). |
| Mutant Screening | ALS-linked mutants (e.g., A315T, M337V) available with sequence verification. |
| Discriminating pathological aggregates from essential nuclear WT function | High-purity WT vs ALS-linked mutant panel (A315T, M337V) with identical sequence-verified backbones |
| Cross-species preclinical translation (cyno / mouse / rat) | Human / Mouse / Rat / Cyno ortholog recombinant proteins available with >95% purity |
| Lack of cellular controls for nuclear vs cytoplasmic mislocalization | Lentivirus-based stable cell lines with tagged ORF; Benchmark Antibodies for localization assays |
| Off-target toxicity due to disruption of physiological RNA splicing | Validated siRNA included for specificity checks and nuclear function rescue studies |
| False Positives | Validated siRNA included for specificity checks in cellular models. |
Live TARDBP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TARDBP (TDP-43) therapeutics is intensifying, with major players shifting focus from symptomatic management to disease-modifying interventions targeting protein aggregation and clearance. As first-generation antisense oligonucleotides and small-molecule disaggregators enter the clinic, the next wave of R&D is targeting intracellular delivery enhancement, gain-of-toxicity versus loss-of-function mechanism resolution, and combination regimens with autophagy modulators. Additionally, mutant-specific clearance and gene-editing approaches are being explored to halt ALS and FTD progression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ASO / Oligonucleotide | Ionis, Biogen | ALS, FTD | Knockdown Validation & Target Engagement (Need High-Purity Controls & siRNA) |
| Small Molecule | Denali, Biogen | ALS, Neurodegeneration | Aggregation Inhibition & Conformational Selectivity (Need WT & Mutant Proteins) |
| PROTAC / Degrader | Arvinas (Emerging) | ALS | Ubiquitination Assay (Need Sequence Verified Targets) |
| Monoclonal Antibody | CNS Extracellular Clearance Consortia | ALS (Extracellular clearance hypothesis) | Immunoassay Development (Need full-length native protein standard) |